• PTC Therapeutics highlighted 2026 guidance for product revenue of USD 750-850 million, total revenue of USD 1.08-1.18 billion, OpEx of USD 680-720 million.
• Sephience posted Q1 2026 global revenue of USD 125 million, including USD 112 million in US revenue, with 1,244 patients on commercial therapy worldwide as of March 31, 2026.
• 2025 revenue totaled USD 831 million, including product revenue of USD 587 million.
• Votoplam Huntington’s disease program moved into Phase 3, with Novartis initiating INVEST-HD targeting about 770 participants, primary endpoint change from baseline in cUHDRS, treatment period up to 36 months.
• Vatiquinone data in Friedreich’s ataxia cited 50% slowing of disease progression over 3 years in a long-term extension study, despite MOVE-FA missing its primary endpoint at 72 weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief on May 10, 2026, and is solely responsible for the information contained therein.